PharmaShots | Incisive News in 3 Shots

Subscribe Now

Beovu

Novartis Reports Results of Beovu (brolucizumab) in P-III KITE & KINGFISHER Trials for the Treatment of Diabetic Macular Edema

Novartis Reports Results of Beovu (brolucizumab) in P-III KITE & KINGFISHER Trials for the Treatment of Diabetic Macular Edema

August 18, 2021

Novartis Reports Results of Beovu (brolucizumab) in Two New Post-Hoc Analyses of P-III HAWK and HARRIER Studies for Wet AMD

Novartis Reports Results of Beovu (brolucizumab) in Two New Post-Hoc Analyses of P-III HAWK and HARRIER Studies for Wet AMD

October 6, 2020

Novartis' Beovu (brolucizumab) Receives EMA's Approval for its Safety Label Update to Treat Wet Age-Related Macular Degeneration

Novartis' Beovu (brolucizumab) Receives EMA's Approval for its Safety Label Update to Treat Wet Age-Related Macular Degeneration

September 15, 2020

Novartis Reports Results of Beovu (brolucizumab) in P-III KITE Study for Diabetic Macular Edema

Novartis Reports Results of Beovu (brolucizumab) in P-III KITE Study for Diabetic Macular Edema

September 14, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us